Home > News > BioSante Pharmaceuticals Signs Option and License
February 27th, 2006
BioSante Pharmaceuticals Signs Option and License
Abstract:
BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that it has signed an exclusive option and license agreement with Medical Aesthetics Technology Corporation ("MATC") for the use of BioSante's calcium phosphate nanotechnology (CaP) in the field of aesthetic medicine.
Source:
businesswire
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||